Hal Gerber, MD

Managing Director

Dr. Gerber has over 20 years experience in the healthcare industry, and advisory experience with a broad range of companies including biotechnology, pharmaceutical, medical device and healthcare services. Prior to joining Burrill & Company, Dr. Gerber was Managing Director and Head of Pharmaceutical and Biotechnology Investment Banking for Wells Fargo Securities, where his responsibilities included mergers & acquisitions, public offerings, private placements, and strategic advisory work. Before joining the predecessor of Wells Fargo Securities in 2000, Dr. Gerber was Executive Director and Head of Life Sciences Investment Banking for Rabobank International in San Francisco. Previously, he headed the bank’s life sciences and healthcare activities in the United Kingdom, France, Spain and Italy from a London base. Dr. Gerber was certified by the UK Securities and Futures Authority. He was also a member of the Bank’s Strategic Advisory Board and the Board of Directors of the Golden Helix Healthcare Award. Dr. Gerber received his undergraduate degree in philosophy from the University of Pennsylvania, where he graduated summa cum laude and was a member of Phi Beta Kappa, and his Doctorate in Medicine from the University of Pennsylvania School of Medicine, where he was awarded membership in Alpha Omega Alpha. He completed an advanced certification in Internal Medicine at the University of California San Francisco and is Board Certified. Earlier in his career, Dr. Gerber did research at NIH. He is currently a member of the National Board of Directors for the American Liver Foundation. Dr. Gerber’s industry experience includes founding a medical diagnostic company, serving as CEO and Chairman, and subsequently selling the company to Quest Diagnostics.